Radiology. Imaging cancer最新文献

{"title":"Malignant Histiocytic Neoplasm of the Mediastinum with Pericardial Involvement in a Child.","authors":"Jessie Huang, Maria Clara Lorca, Irene Y Chen, Apeksha Chaturvedi","doi":"10.1148/rycan.230133","DOIUrl":"10.1148/rycan.230133","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139672533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Screening, Cancer Syndromes, and the Radiologist.","authors":"Peter L Choyke","doi":"10.1148/rycan.240045","DOIUrl":"10.1148/rycan.240045","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140132463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodality Imaging to Direct Management of Primary and Recurrent Rectal Adenocarcinoma Beyond the Total Mesorectal Excision Plane.","authors":"Joshua D Shur, Sheng Qiu, Edward Johnston, Diana Tait, Nicos Fotiadis, Christos Kontovounisios, Shahnawaz Rasheed, Paris Tekkis, Angela Riddell, Dow-Mu Koh","doi":"10.1148/rycan.230077","DOIUrl":"10.1148/rycan.230077","url":null,"abstract":"<p><p>Rectal tumors extending beyond the total mesorectal excision (TME) plane (beyond-TME) require particular multidisciplinary expertise and oncologic considerations when planning treatment. Imaging is used at all stages of the pathway, such as local tumor staging/restaging, creating an imaging-based \"roadmap\" to plan surgery for optimal tumor clearance, identifying treatment-related complications, which may be suitable for radiology-guided intervention, and to detect recurrent or metastatic disease, which may be suitable for radiology-guided ablative therapies. Beyond-TME and exenterative surgery have gained acceptance as potentially curative procedures for advanced tumors. Understanding the role, techniques, and pitfalls of current imaging techniques is important for both radiologists involved in the treatment of these patients and general radiologists who may encounter patients undergoing surveillance or patients presenting with surgical complications or intercurrent abdominal pathology. This review aims to outline the current and emerging roles of imaging in patients with beyond-TME and recurrent rectal malignancy, focusing on practical tips for image interpretation and surgical planning in the beyond-TME setting. <b>Keywords:</b> Abdomen/GI, Rectum, Oncology © RSNA, 2024.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139741864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing Metabolic Heterogeneity of Hepatocellular Carcinoma with Hyperpolarized ¹³C Pyruvate MRI and Mass Spectrometry.","authors":"Qianhui Dou, Aaron K Grant, Patricia Coutinto de Souza, Marwan Moussa, Imad Nasser, Muneeb Ahmed, Leo L Tsai","doi":"10.1148/rycan.230056","DOIUrl":"10.1148/rycan.230056","url":null,"abstract":"<p><p>Purpose To characterize the metabolomic profiles of two hepatocellular carcinoma (HCC) rat models, track evolution of these profiles to a stimulated tumor state, and assess their effect on lactate flux with hyperpolarized (HP) carbon 13 (¹³C) MRI. Materials and Methods Forty-three female adult Fischer rats were implanted with N1S1 or McA-RH7777 HCC tumors. In vivo lactate-to-pyruvate ratio (LPR) was measured with HP ¹³C MRI at 9.4 T. Ex vivo mass spectrometry was used to measure intratumoral metabolites, and Ki67 labeling was used to quantify proliferation. Tumors were first compared with three normal liver controls. The tumors were then compared with stimulated variants via off-target hepatic thermal ablation treatment. All comparisons were made using the Mann-Whitney test. Results HP ¹³C pyruvate MRI showed greater LPR in N1S1 tumors compared with normal liver (mean [SD], 0.564 ± 0.194 vs 0.311 ± 0.057; <i>P</i> < .001 [<i>n</i> = 9]), but not for McA-RH7777 (<i>P</i> = .44 [<i>n</i> = 8]). Mass spectrometry confirmed that the glycolysis pathway was increased in N1S1 tumors and decreased in McA-RH7777 tumors. The pentose phosphate pathway was also decreased only in McA-RH7777 tumors. Increased proliferation in stimulated N1S1 tumors corresponded to a net increase in LPR (six stimulated vs six nonstimulated, 0.269 ± 0.148 vs 0.027 ± 0.08; <i>P</i> = .009), but not in McA-RH7777 (eight stimulated vs six nonstimulated, <i>P</i> = .13), despite increased proliferation and metastases. Mass spectrometry demonstrated relatively increased lactate production with stimulation in N1S1 tumors only. Conclusion Two HCC subtypes showed divergent glycolytic dependency at baseline and during transformation to a high proliferation state. This metabolic heterogeneity in HCC should be considered with use of HP ¹³C MRI for diagnosis and tracking. <b>Keywords:</b> Molecular Imaging-Probe Development, Liver, Abdomen/GI, Oncology, Hepatocellular Carcinoma © RSNA, 2024 See also commentary by Ohliger in this issue.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.","authors":"Devan Diwanji, Natsuko Onishi, Deep K Hathi, Courtney Lawhn-Heath, John Kornak, Wen Li, Ruby Guo, Julissa Molina-Vega, Youngho Seo, Robert R Flavell, Diane Heditsian, Susie Brain, Laura J Esserman, Bonnie N Joe, Nola M Hylton, Ella F Jones, Kimberly M Ray","doi":"10.1148/rycan.230082","DOIUrl":"10.1148/rycan.230082","url":null,"abstract":"<p><p>Purpose To compare quantitative measures of tumor metabolism and perfusion using fluorine 18 (¹⁸F) fluorodeoxyglucose (FDG) dedicated breast PET (dbPET) and breast dynamic contrast-enhanced (DCE) MRI during early treatment with neoadjuvant chemotherapy (NAC). Materials and Methods Prospectively collected DCE MRI and ¹⁸F-FDG dbPET examinations were analyzed at baseline (T0) and after 3 weeks (T1) of NAC in 20 participants with 22 invasive breast cancers. FDG dbPET-derived standardized uptake value (SUV), metabolic tumor volume, and total lesion glycolysis (TLG) and MRI-derived percent enhancement (PE), signal enhancement ratio (SER), and functional tumor volume (FTV) were calculated at both time points. Differences between FDG dbPET and MRI parameters were evaluated after stratifying by receptor status, Ki-67 index, and residual cancer burden. Parameters were compared using Wilcoxon signed rank and Mann-Whitney <i>U</i> tests. Results High Ki-67 tumors had higher baseline SUV_mean (difference, 5.1; <i>P</i> = .01) and SUV_peak (difference, 5.5; <i>P</i> = .04). At T1, decreases were observed in FDG dbPET measures (pseudo-median difference T0 minus T1 value [95% CI]) of SUV_max (-6.2 [-10.2, -2.6]; <i>P</i> < .001), SUV_mean (-2.6 [-4.9, -1.3]; <i>P</i> < .001), SUV_peak (-4.2 [-6.9, -2.3]; <i>P</i> < .001), and TLG (-29.1 mL³ [-71.4, -6.8]; <i>P</i> = .005) and MRI measures of SER_peak (-1.0 [-1.3, -0.2]; <i>P</i> = .02) and FTV (-11.6 mL³ [-22.2, -1.7]; <i>P</i> = .009). Relative to nonresponsive tumors, responsive tumors showed a difference (95% CI) in percent change in SUV_max of -34.3% (-55.9%, 1.5%; <i>P</i> = .06) and in PE_peak of -42.4% (95% CI: -110.5%, 8.5%; <i>P</i> = .08). Conclusion ¹⁸F-FDG dbPET was sensitive to early changes during NAC and provided complementary information to DCE MRI that may be useful for treatment response evaluation. <b>Keywords:</b> Breast, PET, Dynamic Contrast-enhanced MRI Clinical trial registration no. NCT01042379 <i>Supplemental material is available for this article.</i> © RSNA, 2024.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140319102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative US Delta Radiomics to Predict Radiation Response in Individuals with Head and Neck Squamous Cell Carcinoma.","authors":"Laurentius Oscar Osapoetra, Archya Dasgupta, Daniel DiCenzo, Kashuf Fatima, Karina Quiaoit, Murtuza Saifuddin, Irene Karam, Ian Poon, Zain Husain, William T Tran, Lakshmanan Sannachi, Gregory J Czarnota","doi":"10.1148/rycan.230029","DOIUrl":"10.1148/rycan.230029","url":null,"abstract":"<p><p>Purpose To investigate the role of quantitative US (QUS) radiomics data obtained after the 1st week of radiation therapy (RT) in predicting treatment response in individuals with head and neck squamous cell carcinoma (HNSCC). Materials and Methods This prospective study included 55 participants (21 with complete response [median age, 65 years {IQR: 47-80 years}, 20 male, one female; and 34 with incomplete response [median age, 59 years {IQR: 39-79 years}, 33 male, one female) with bulky node-positive HNSCC treated with curative-intent RT from January 2015 to October 2019. All participants received 70 Gy of radiation in 33-35 fractions over 6-7 weeks. US radiofrequency data from metastatic lymph nodes were acquired prior to and after 1 week of RT. QUS analysis resulted in five spectral maps from which mean values were extracted. We applied a gray-level co-occurrence matrix technique for textural analysis, leading to 20 QUS texture and 80 texture-derivative parameters. The response 3 months after RT was used as the end point. Model building and evaluation utilized nested leave-one-out cross-validation. Results Five delta (Δ) parameters had statistically significant differences (<i>P</i> < .05). The support vector machines classifier achieved a sensitivity of 71% (15 of 21), a specificity of 76% (26 of 34), a balanced accuracy of 74%, and an area under the receiver operating characteristic curve of 0.77 on the test set. For all the classifiers, the performance improved after the 1st week of treatment. Conclusion A QUS Δ-radiomics model using data obtained after the 1st week of RT from individuals with HNSCC predicted response 3 months after treatment completion with reasonable accuracy. <b>Keywords:</b> Computer-Aided Diagnosis (CAD), Ultrasound, Radiation Therapy/Oncology, Head/Neck, Radiomics, Quantitative US, Radiotherapy, Head and Neck Squamous Cell Carcinoma, Machine Learning Clinicaltrials.gov registration no. NCT03908684 <i>Supplemental material is available for this article.</i> © RSNA, 2024.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139932640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiologic-Pathologic Correlation of Nonmass Enhancement Contiguous with Malignant Index Breast Cancer Masses at Preoperative Breast MRI.","authors":"Derek L Nguyen, Mira Lotfalla, Ashley Cimino-Mathews, Mehran Habibi, Emily B Ambinder","doi":"10.1148/rycan.230060","DOIUrl":"10.1148/rycan.230060","url":null,"abstract":"<p><p>Purpose To determine the pathologic features of nonmass enhancement (NME) directly adjacent to biopsy-proven malignant masses (index masses) at preoperative MRI and determine imaging characteristics that are associated with a malignant pathologic condition. Materials and Methods This retrospective study involved the review of breast MRI and mammography examinations performed for evaluating disease extent in patients newly diagnosed with breast cancer from July 1, 2016, to September 30, 2019. Inclusion criteria were limited to patients with an index mass and the presence of NME extending directly from the mass margins. Wilcoxon rank sum test, Fisher exact test, and χ² test were used to analyze cancer, patient, and imaging characteristics associated with the NME diagnosis. Results Fifty-eight patients (mean age, 58 years ± 12 [SD]; all women) were included. Malignant pathologic findings for mass-associated NME occurred in 64% (37 of 58) of patients, 43% (16 of 37) with ductal carcinoma in situ and 57% (21 of 37) with invasive carcinoma. NME was more likely to be malignant when associated with an index cancer that had a low Ki-67 index (<20%) (<i>P</i> = .04). The presence of calcifications at mammography correlating with mass-associated NME was not significantly associated with malignant pathologic conditions (<i>P</i> = .19). The span of suspicious enhancement measured at MRI overestimated the true span of disease at histologic evaluation (<i>P</i> < .001), while there was no evidence of a difference between span of calcifications at mammography and true span of disease at histologic evaluation (<i>P</i> = .27). Conclusion Mass-associated NME at preoperative MRI was malignant in most patients with newly diagnosed breast cancer. The span of suspicious enhancement measured at MRI overestimated the true span of disease found at histologic evaluation. <b>Keywords:</b> Breast, Mammography © RSNA, 2024 See also the commentary by Newell in this issue.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139672534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Detection Using a Low-Dose Positron Emission Digital Mammography System.","authors":"Vivianne Freitas, Xuan Li, Anabel Scaranelo, Frederick Au, Supriya Kulkarni, Sandeep Ghai, Samira Taeb, Oleksandr Bubon, Brandon Baldassi, Borys Komarov, Shayna Parker, Craig A Macsemchuk, Michael Waterston, Kenneth O Olsen, Alla Reznik","doi":"10.1148/rycan.230020","DOIUrl":"10.1148/rycan.230020","url":null,"abstract":"<p><p>Purpose To investigate the feasibility of low-dose positron emission mammography (PEM) concurrently to MRI to identify breast cancer and determine its local extent. Materials and Methods In this research ethics board-approved prospective study, participants newly diagnosed with breast cancer with concurrent breast MRI acquisitions were assigned independently of breast density, tumor size, and histopathologic cancer subtype to undergo low-dose PEM with up to 185 MBq of fluorine 18-labeled fluorodeoxyglucose (¹⁸F-FDG). Two breast radiologists, unaware of the cancer location, reviewed PEM images taken 1 and 4 hours following ¹⁸F-FDG injection. Findings were correlated with histopathologic results. Detection accuracy and participant details were examined using logistic regression and summary statistics, and a comparative analysis assessed the efficacy of PEM and MRI additional lesions detection (ClinicalTrials.gov: NCT03520218). Results Twenty-five female participants (median age, 52 years; range, 32-85 years) comprised the cohort. Twenty-four of 25 (96%) cancers (19 invasive cancers and five in situ diseases) were identified with PEM from 100 sets of bilateral images, showcasing comparable performance even after 3 hours of radiotracer uptake. The median invasive cancer size was 31 mm (range, 10-120). Three additional in situ grade 2 lesions were missed at PEM. While not significant, PEM detected fewer false-positive additional lesions compared with MRI (one of six [16%] vs eight of 13 [62%]; <i>P</i> = .14). Conclusion This study suggests the feasibility of a low-dose PEM system in helping to detect invasive breast cancer. Though large-scale clinical trials are essential to confirm these preliminary results, this study underscores the potential of this low-dose PEM system as a promising imaging tool in breast cancer diagnosis. ClinicalTrials.gov registration no. NCT03520218 <b>Keywords:</b> Positron Emission Digital Mammography, Invasive Breast Cancer, Oncology, MRI <i>Supplemental material is available for this article.</i> © RSNA, 2024 See also commentary by Barreto and Rapelyea in this issue.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139707638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Osteosarcoma of the Sternum with Lung Metastases.","authors":"Anitha Mandava, Sanath Kandem, Rakesh Juluri, Arvind K Reddy, Veeraiah Koppula","doi":"10.1148/rycan.230199","DOIUrl":"10.1148/rycan.230199","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139932639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calvarial Epithelioid Hemangioendothelioma Mimicking Osteosarcoma.","authors":"Yashaswi Singh, Amit Gupta, Asit Ranjan Mridha, Krithika Rangarajan","doi":"10.1148/rycan.230198","DOIUrl":"10.1148/rycan.230198","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140060370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}